Our study, leveraging liquid biopsy technology, successfully extended these prior findings by enabling the analysis of a larger patient cohort to provide a more comprehensive understanding of the genomic landscape of BRAF alterations in lung cancer. This evidence concerns the gene BRAF and lung cancer.